Koers Ampliphi Biosciences Corp Nyse
Aandelen
APHB
US03211P2020
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 4,54 mln. 4,23 mln. | Omzet 2025 * | 2,75 mln. 2,56 mln. | Marktkapitalisatie | 97,62 mln. 90,96 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -72 mln. -67,09 mln. | Nettowinst (verlies) 2025 * | -67 mln. -62,43 mln. | EV/omzet 2024 * | 21,5 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 35,5 x |
K/w-verhouding 2024 * |
-1,42
x | K/w-verhouding 2025 * |
-2,08
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 29,72% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 11-07-23 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 26-10-20 |
Bryan Kadotani
PRN | Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 64 | 12-02-20 | |
Joseph Patti
BRD | Director/Board Member | 60 | 09-05-19 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,64% | 53,67 mld. | |
+33,67% | 38,86 mld. | |
-7,67% | 38,76 mld. | |
-10,77% | 27,27 mld. | |
+12,16% | 25,91 mld. | |
-17,70% | 20,29 mld. | |
+35,00% | 12,78 mld. | |
+29,88% | 12,18 mld. | |
-2,92% | 11,96 mld. |